BRPI0410222A - tratamento de distúrbios bipolares e sintomas associados - Google Patents

tratamento de distúrbios bipolares e sintomas associados

Info

Publication number
BRPI0410222A
BRPI0410222A BRPI0410222-3A BRPI0410222A BRPI0410222A BR PI0410222 A BRPI0410222 A BR PI0410222A BR PI0410222 A BRPI0410222 A BR PI0410222A BR PI0410222 A BRPI0410222 A BR PI0410222A
Authority
BR
Brazil
Prior art keywords
treatment
bipolar
bipolar disorder
mammal
associated symptoms
Prior art date
Application number
BRPI0410222-3A
Other languages
English (en)
Inventor
Earl Laux Giller Jr
Edmund Harrigan
James Herbert Heym
Steven Joseph Romano
Thomas Francis Seeger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0410222A publication Critical patent/BRPI0410222A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"TRATAMENTO DE DISTúRBIOS BIPOLARES E SINTOMAS ASSOCIADOS". A presente invenção refere-se a um método para tratamentos relacionados com distúrbio bipolar num mamífero, incluindo um humano, os tratamentos incluem tratamento de distúrbio bipolar de ciclo rápido, tratamento de sintomas de distúrbio bipolar selecionados do grupo consistindo de obsessão aguda e depressão, tratamento para efetuar a estabilização do humor; tratamento para a prevenção da reincidência em episódios bipolares, e para o tratamento de pensamentos e tendências suicidas associados com o distúrbio bipolar, consistindo na administração ao referido mamífero de uma quantidade eficaz de um composto da fórmula (I): ou um sal de adição ácido farmaceuticamente aceitável seu, em que Ar, n, X, e Y são como definidos.
BRPI0410222-3A 2003-05-16 2004-05-12 tratamento de distúrbios bipolares e sintomas associados BRPI0410222A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47145003P 2003-05-16 2003-05-16
PCT/IB2004/001601 WO2004100957A1 (en) 2003-05-16 2004-05-12 Treatment of bipolar disorders and associated symptoms

Publications (1)

Publication Number Publication Date
BRPI0410222A true BRPI0410222A (pt) 2006-05-09

Family

ID=33452446

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410222-3A BRPI0410222A (pt) 2003-05-16 2004-05-12 tratamento de distúrbios bipolares e sintomas associados

Country Status (13)

Country Link
US (1) US20050038036A1 (pt)
EP (1) EP1626723A1 (pt)
JP (1) JP2007516955A (pt)
KR (1) KR20060009938A (pt)
CN (1) CN1780626A (pt)
AR (1) AR046586A1 (pt)
AU (1) AU2004237961A1 (pt)
BR (1) BRPI0410222A (pt)
CA (1) CA2525326A1 (pt)
MX (1) MXPA05012320A (pt)
TW (1) TW200509929A (pt)
WO (1) WO2004100957A1 (pt)
ZA (1) ZA200508523B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
WO2008046046A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
CA2666143A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
AR063280A1 (es) * 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN105218565A (zh) * 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
NZ507981A (en) * 1998-05-29 2003-10-31 Lilly Co Eli Combination therapy for treatment of bipolar disorders

Also Published As

Publication number Publication date
KR20060009938A (ko) 2006-02-01
WO2004100957A1 (en) 2004-11-25
AU2004237961A1 (en) 2004-11-25
CA2525326A1 (en) 2004-11-25
TW200509929A (en) 2005-03-16
EP1626723A1 (en) 2006-02-22
AR046586A1 (es) 2005-12-14
ZA200508523B (en) 2007-04-25
MXPA05012320A (es) 2006-01-30
JP2007516955A (ja) 2007-06-28
US20050038036A1 (en) 2005-02-17
CN1780626A (zh) 2006-05-31

Similar Documents

Publication Publication Date Title
Dall'lgna et al. Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
TW200509929A (en) Treatment of bipolar disorders and associated symptoms
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
BR0014179A (pt) Modernos derivados de ácido aminodicarboxìlico com propriedades farmacêuticas
BRPI0410786A (pt) composição, uso da mesma, e, método de tratamento de um distúrbio de humor em um paciente
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
US5137712A (en) Use of s-adenosyl-l-methionine (SAMe) to reverse and/or prevent supersensitivity, tolerance and extrapyramidal side effects induced by neuroleptic treatment
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR0308222A (pt) Terapias de combinação para tratar células deficientes em metiltioadenosina fosforilase
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0408490A (pt) composições que compreendem ácidos graxos e aminoácidos
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
BR0116749A (pt) usos de artemina ou seu agonista e artigo manufaturado
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
MX2007004485A (es) Tratamiento de desordenes bipolares y sintomas asociados.
BR9812577A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas
BRPI0607536A2 (pt) tratamento de dor
Bariotto‐dos‐Santos et al. Repurposing an established drug: an emerging role for methylene blue in L‐DOPA‐induced dyskinesia
Nadipelly et al. Effect of certain trimethoxy flavones on paclitaxel-induced peripheral neuropathy in mice
BRPI0408004A (pt) composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias
Mayanagi et al. Systemic administration of diazoxide induces delayed preconditioning against transient focal cerebral ischemia in rats
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
Dutta et al. Indian red scorpion venom-induced augmentation of cardio-respiratory reflexes and pulmonary edema involve the release of histamine
Maćkowiak et al. MK-801, a NMDA receptor antagonist, increases phosphorylation of histone H3 in the rat medial prefrontal cortex

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2142 DE 24/01/2012.